Healthy volunteers help test new drug form
NCT ID NCT07206043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new, stronger version of the drug RPH-104 (goflikicept) in 130 healthy volunteers aged 18-45. Participants received a single injection either under the skin or into a vein at different doses. The goal was to check how the drug moves through the body, its safety, and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- goflikicept (RPH-104)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Llc "Research Lab"
Moscow, 127521, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?